Skip to Main Content

Pilot Phase 2 Study of Intratumoral G100 in Patients With Cutaneous T Cell Lymphoma

Conditions

Non-Hodgkin's Lymphoma

Phase II

What is the purpose of this trial?

The overall goal of this study is to evaluate the safety and immunogenicity of repeat-dose intratumoral G100 administration in patients with Cutaneous T Cell Lymphoma (CTCL) alone (Part 1) and following standard local radiation therapy or topical nitrogen mustard application (Part 2). Plaque, patch, or tumor lesions of CTCL may be injected. Disease will be assessed in all sites, including skin, nodes, and blood.

  • Trial with
    Yale Cancer Center
  • Start Date
    03/23/2019
  • End Date
    12/30/2019
Trial Image

For more information about this study, contact:

Laura Leary

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    05/19/2019
  • Study HIC
    #2000021483